Rapamune Oral Solution,Tablets

Drugspedia.net

|Rapamune Oral Solution,Tablets

Drugs search, click the first letter of a drug name: | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9

   


Rapamune


Generic Name: sirolimus
Dosage Form: Oral solution,tablets

Rx only

WARNING:

Increased susceptibility to infection and the possible development of lymphoma may result from immunosuppression. Only physicians experienced in immunosuppressive therapy and management of renal transplant patients should use Rapamune®. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.

Rapamune Description

Rapamune® (sirolimus) is an immunosuppressive agent. Sirolimus is a macrocyclic lactone produced by Streptomyces hygroscopicus. The chemical name of sirolimus (also known as rapamycin) is (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS) - 9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a - hexadecahydro - 9,27 - dihydroxy - 3 - [(1R) - 2 - [(1S,3R,4R) - 4 - hydroxy - 3 - methoxycyclohexyl] - 1 - methylethyl] - 10,21 - dimethoxy - 6,8,12,14,20,26 - hexamethyl - 23,27 - epoxy - 3H - pyrido[2,1 - c][1,4] oxaazacyclohentriacontine-1,5,11,28,29 (4H,6H,31H)-pentone. Its molecular formula is C51H79NO13 and its molecular weight is 914.2. The structural formula of sirolimus is shown below.



Sirolimus is a white to off-white powder and is insoluble in water, but freely soluble in benzyl alcohol, chloroform, acetone, and acetonitrile.

Rapamune® is available for administration as an oral solution containing 1 mg/mL sirolimus. Rapamune is also available as a white, triangular-shaped tablet containing 1-mg sirolimus, and as a yellow to beige triangular-shaped tablet containing 2-mg sirolimus.

The inactive ingredients in Rapamune® Oral Solution are Phosal 50 PG® (phosphatidylcholine, propylene glycol, mono- and di-glycerides, ethanol, soy fatty acids, and ascorbyl palmitate) and polysorbate 80. Rapamune Oral Solution contains 1.5% - 2.5% ethanol.

The inactive ingredients in Rapamune® Tablets include sucrose, lactose, polyethylene glycol 8000, calcium sulfate, microcrystalline cellulose, pharmaceutical glaze, talc, titanium dioxide, magnesium stearate, povidone, poloxamer 188, polyethylene glycol 20,000, glyceryl monooleate, carnauba wax, dl-alpha tocopherol, and other ingredients. The 2 mg dosage strength also contains iron oxide yellow 10 and iron oxide brown 70.

Rapamune - Clinical Pharmacology

Mechanism Of Action

Sirolimus inhibits T lymphocyte activation and proliferation that occurs in response to antigenic and cytokine (Interleukin [IL]-2, IL-4, and IL-15) stimulation by a mechanism that is distinct from that of other immunosuppressants. Sirolimus also inhibits antibody production. In cells, sirolimus binds to the immunophilin, FK Binding Protein-12 (FKBP-12), to generate an immunosuppressive complex. The sirolimus:FKBP-12 complex has no effect on calcineurin activity. This complex binds to and inhibits the activation of the mammalian Target Of Rapamycin (mTOR), a key regulatory kinase. This inhibition suppresses cytokine-driven T-cell proliferation, inhibiting the progression from the G1 to the S phase of the cell cycle.

Studies in experimental models show that sirolimus prolongs allograft (kidney, heart, skin, islet, small bowel, pancreatico-duodenal, and bone marrow) survival in mice, rats, pigs, and/or primates. Sirolimus reverses acute rejection of heart and kidney allografts in rats and prolongs the graft survival in presensitized rats. In some studies, the immunosuppressive effect of sirolimus lasts up to 6 months after discontinuation of therapy. This tolerization effect is alloantigen specific.

In rodent models of autoimmune disease, sirolimus suppresses immune-mediated events associated with systemic lupus erythematosus, collagen-induced arthritis, autoimmune type I diabetes, autoimmune myocarditis, experimental allergic encephalomyelitis, graft-versus-host disease, and autoimmune uveoretinitis.

Pharmacokinetics

Sirolimus pharmacokinetic activity has been determined following oral administration in healthy subjects, pediatric patients, hepatically-impaired patients, and renal transplant patients.

Absorption

Following administration of Rapamune® Oral Solution, sirolimus is rapidly absorbed, with a mean time-to-peak concentration (tmax) of approximately 1 hour after a single dose in healthy subjects and approximately 2 hours after multiple oral doses in renal transplant recipients. The systemic availability of sirolimus was estimated to be approximately 14% after the administration of Rapamune Oral Solution. The mean bioavailability of sirolimus after administration of the tablet is about 27% higher relative to the oral solution. Sirolimus oral tablets are not bioequivalent to the oral solution; however, clinical equivalence has been demonstrated at the 2-mg dose level. (See Clinical Studies and DOSAGE AND ADMINISTRATION). Sirolimus concentrations, following the administration of Rapamune Oral Solution to stable renal transplant patients, are dose proportional between 3 and 12 mg/m2.

Food effects: In 22 healthy volunteers receiving Rapamune Oral Solution, a high-fat meal (861.8 kcal, 54.9% kcal from fat) altered the bioavailability characteristics of sirolimus. Compared with fasting, a 34% decrease in the peak blood sirolimus concentration (Cmax), a 3.5‑fold increase in the time-to-peak concentration (tmax), and a 35% increase in total exposure (AUC) was observed. After administration of Rapamune Tablets and a high-fat meal in 24 healthy volunteers, Cmax, tmax, and AUC showed increases of 65%, 32%, and 23%, respectively. To minimize variability, both Rapamune Oral Solution and Tablets should be taken consistently with or without food (See DOSAGE AND ADMINISTRATION).

Distribution

The mean (± SD) blood-to-plasma ratio of sirolimus was 36 ± 18 in stable renal allograft recipients after administration of oral solution, indicating that sirolimus is extensively partitioned into formed blood elements. The mean volume of distribution (Vss/F) of sirolimus is 12 ± 8 L/kg. Sirolimus is extensively bound (approximately 92%) to human plasma proteins. In man, the binding of sirolimus was shown mainly to be associated with serum albumin (97%), α1-acid glycoprotein, and lipoproteins.

Metabolism

Sirolimus is a substrate for both cytochrome P450 IIIA4 (CYP3A4) and P-glycoprotein (P-gp). Sirolimus is extensively metabolized by the CYP3A4 isozyme in the intestinal wall and liver and undergoes counter-transport from enterocytes of the small intestine into the gut lumen by the P‑gp drug efflux pump. Sirolimus is potentially recycled between enterocytes and the gut lumen to allow continued metabolism by CYP3A4. Therefore, absorption and subsequent elimination of systemically absorbed sirolimus may be influenced by drugs that affect these proteins. Inhibitors of CYP3A4 and P-gp increase sirolimus concentrations. Inducers of CYP3A4 and P-gp decrease sirolimus concentrations. (See WARNINGS and PRECAUTIONS, Drug Interactions and Other drug interactions). Sirolimus is extensively metabolized by O-demethylation and/or hydroxylation. Seven (7) major metabolites, including hydroxy, demethyl, and hydroxydemethyl, are identifiable in whole blood. Some of these metabolites are also detectable in plasma, fecal, and urine samples. Glucuronide and sulfate conjugates are not present in any of the biologic matrices. Sirolimus is the major component in human whole blood and contributes to more than 90% of the immunosuppressive activity.

Excretion

After a single dose of [14C]sirolimus oral solution in healthy volunteers, the majority (91%) of radioactivity was recovered from the feces, and only a minor amount (2.2%) was excreted in urine.

Pharmacokinetics In Renal Transplant Patients

Rapamune Oral Solution: Pharmacokinetic parameters for sirolimus oral solution given daily in combination with cyclosporine and corticosteroids in renal transplant patients are summarized below based on data collected at months 1, 3, and 6 after transplantation (Studies 1 and 2; see CLINICAL STUDIES). There were no significant differences in any of these parameters with respect to treatment group or month.

SIROLIMUS PHARMACOKINETIC PARAMETERS (MEAN ± SD) IN RENAL TRANSPLANT PATIENTS (MULTIPLE DOSE ORAL SOLUTION)a,b
Cmax,ssc tmax,ss AUCτ,ssc CL/F/WTd
N Dose (ng/mL) (h) (ng•h/mL) (mL/h/kg)

a: Sirolimus administered four hours after cyclosporine oral solution (MODIFIED) (e.g., Neoral® Oral Solution) and/or cyclosporine capsules (MODIFIED) (e.g., Neoral® Soft Gelatin Capsules).
b: As measured by the Liquid Chromatographic/Tandem Mass Spectrometric Method (LC/MS/MS).
c: These parameters were dose normalized prior to the statistical comparison.
d: CL/F/WT = oral dose clearance.

19 2 mg 12.2 ± 6.2 3.01 ± 2.40 158 ± 70 182 ± 72
23 5 mg 37.4 ± 21 1.84 ± 1.30 396 ± 193 221 ± 143

Whole blood sirolimus trough concentrations (mean ± SD), expressed as chromatographic assay values, for the 2 mg/day and 5 mg/day dose groups were 6.9 ± 3.2 ng/mL (n = 226) and 13.8 ± 5.9 ng/mL (n = 219), respectively (see DOSAGE AND ADMINISTRATION). Whole blood trough sirolimus concentrations, as measured by LC/MS/MS, were significantly correlated (r2 = 0.96) with AUCτ,ss. Upon repeated twice daily administration without an initial loading dose in a multiple-dose study, the average trough concentration of sirolimus increases approximately 2 to 3-fold over the initial 6 days of therapy at which time steady state is reached. A loading dose of 3 times the maintenance dose will provide near steady-state concentrations within 1 day in most patients. The mean ± SD terminal elimination half life (t½) of sirolimus after multiple dosing in stable renal transplant patients was estimated to be about 62 ± 16 hours.

Rapamune Tablets: Pharmacokinetic parameters for sirolimus tablets administered daily in combination with cyclosporine and corticosteroids in renal transplant patients are summarized below based on data collected at months 1 and 3 after transplantation (Study 3; see CLINICAL STUDIES).

SIROLIMUS PHARMACOKINETIC PARAMETERS (MEAN ± SD) IN RENAL TRANSPLANT PATIENTS (MULTIPLE DOSE TABLETS)a,b
Dose Cmax,ssc tmax,ss AUCτ,ssc CL/F/WTd
n (2 mg/day) (ng/mL) (h) (ng•h/mL) (mL/h/kg)

a: Sirolimus administered four hours after cyclosporine oral solution (MODIFIED) (e.g., Neoral® Oral Solution) and/or cyclosporine capsules (MODIFIED) (e.g., Neoral® Soft Gelatin Capsules).
b: As measured by the Liquid Chromatographic/Tandem Mass Spectrometric Method (LC/MS/MS).
c: These parameters were dose normalized prior to the statistical comparison.
d: CL/F/WT = oral dose clearance.

17 Oral solution 14.4 ± 5.3 2.12 ± 0.84 194 ± 78 173 ± 50
13 Tablets 15.0 ± 4.9 3.46 ± 2.40 230 ± 67 139 ± 63

Whole blood sirolimus trough concentrations (mean ± SD), expressed as chromatographic assay values, for 2 mg of oral solution and 2 mg of tablets over 6 months, were 7.1 ± 3.5 ng/mL (n = 172) and 7.6 ± 3.1 ng/mL (n = 179), respectively (see DOSAGE AND ADMINISTRATION). Whole blood trough sirolimus concentrations, as measured by LC/MS/MS, were significantly correlated (r2 = 0.85) with AUCτ,ss. Mean whole blood sirolimus trough concentrations in patients receiving either Rapamune Oral Solution or Rapamune Tablets with a loading dose of three times the maintenance dose achieved steady-state concentrations within 24 hours after the start of dose administration.

Average Rapamune doses and sirolimus whole blood trough concentrations for tablets administered daily in combination with cyclosporine and following cyclosporine withdrawal, in combination with corticosteroids in renal transplant patients (Study 4; see CLINICAL STUDIES) are summarized in the table below.

AVERAGE Rapamune DOSES AND SIROLIMUS TROUGH CONCENTRATIONS (MEAN ± SD) IN LOW‑ TO MODERATE‑ RISK RENAL TRANSPLANT PATIENTS AFTER MULTIPLE DOSE TABLET ADMINISTRATION
Rapamune with
Cyclosporine Therapya
Rapamune Following
Cyclosporine Withdrawala

a: 215 patients were randomized to each group.
b: Expressed as chromatographic assay values and equivalence.

Rapamune Dose (mg/day)
   Months 4 to 12 2.1 ± 0.7 8.2 ± 4.2
   Months 12 to 24 2.0 ± 0.8 6.4 ± 3.0
   Months 24 to 36 2.0 ± 0.8 5.3 ± 2.5
Sirolimus Cmin, (ng/mL)b
   Months 4 to 12 8.6 ± 3.0 18.6 ± 4.0
   Months 12 to 24 9.0 ± 3.3 18.0 ± 3.8
   Months 24 to 36 9.1 ± 3.4 16.3 ± 4.3

The withdrawal of cyclosporine and concurrent increases in sirolimus trough concentrations to steady-state required approximately 6 weeks. Larger Rapamune® doses were required due to the absence of the inhibition of sirolimus metabolism and transport by cyclosporine and to achieve higher target concentrations during concentration-controlled administration following cyclosporine withdrawal.

Average Rapamune doses and sirolimus whole blood trough concentrations for tablets administered daily in combination with cyclosporine and corticosteroids in high-risk renal transplant patients (Study 5; see CLINICAL STUDIES) are summarized in the table below.

AVERAGE Rapamune DOSES AND SIROLIMUS TROUGH CONCENTRATIONS (MEAN ± SD) IN HIGH-RISK RENAL TRANSPLANT PATIENTS AFTER MULTIPLE-DOSE TABLET ADMINISTRATION
Rapamune with
Cyclosporine Therapy

a: Expressed by chromatography
b: n=109
c: n=113
d: n=127

Rapamune Dose (mg/day)
   Months 3 to 6 5.1 ± 2.4
   Months 6 to 9 5.1 ± 2.3
   Months 9 to 12 5.0 ± 2.3
Sirolimus Cmin (ng/mL)a
   Months 3 to 6b 11.8 ± 4.2
   Months 6 to 9c 11.3 ± 5.2
   Months 9 to 12d 11.2 ± 3.8

Special Populations

Hepatic impairment: Sirolimus oral solution (15 mg) was administered as a single oral dose to 18 subjects with normal hepatic function and to 18 patients with Child-Pugh classification A or B hepatic impairment, in which hepatic impairment was primary and not related to an underlying systemic disease. Shown below are the mean ± SD pharmacokinetic parameters following the administration of sirolimus oral solution.

SIROLIMUS PHARMACOKINETIC PARAMETERS (MEAN ± SD) IN 18 HEALTHY SUBJECTS AND 18 PATIENTS WITH HEPATIC IMPAIRMENT (15 MG SINGLE DOSE – ORAL SOLUTION)
Population Cmax,ssa tmax AUC0-∞ CL/F/WT
(ng/mL) (h) (ng•h/mL) (mL/h/kg)

a: As measured by LC/MS/MS.

Healthy subjects 78.2 ± 18.3 0.82 ± 0.17 970 ± 272 215 ± 76
Hepatic impairment 77.9 ± 23.1 0.84 ± 0.17 1567 ± 616 144 ± 62

Compared with the values in the normal hepatic group, the hepatic impairment group had higher mean values for sirolimus AUC (61%) and t1/2 (43%) and had lower mean values for sirolimus CL/F/WT (33%). The mean t1/2 increased from 79 ± 12 hours in subjects with normal hepatic function to 113 ± 41 hours in patients with impaired hepatic function. The rate of absorption of sirolimus was not altered by hepatic disease, as evidenced by Cmax and tmax values. However, hepatic diseases with varying etiologies may show different effects and the pharmacokinetics of sirolimus in patients with severe hepatic dysfunction is unknown. Dosage adjustment is recommended for patients with mild to moderate hepatic impairment (see DOSAGE AND ADMINISTRATION).

Renal impairment: The effect of renal impairment on the pharmacokinetics of sirolimus is not known. However, there is minimal (2.2%) renal excretion of the drug or its metabolites.

Pediatric: Sirolimus pharmacokinetic data were collected in concentration-controlled trials of pediatric renal transplant patients who were also receiving cyclosporine and corticosteroids. The target ranges for trough concentrations were either 10-20 ng/mL for the 21 children receiving tablets, or 5-15 ng/mL for the one child receiving oral solution. The children aged 6-11 years (n = 8) received mean ± SD doses of 1.75 ± 0.71 mg/day (0.064 ± 0.018 mg/kg, 1.65 ± 0.43 mg/m2). The children aged 12-18 years (n = 14) received mean ± SD doses of 2.79 ± 1.25 mg/day (0.053 ± 0.0150 mg/kg, 1.86 ± 0.61 mg/m2). At the time of sirolimus blood sampling for pharmacokinetic evaluation, the majority (80%) of these pediatric patients received the sirolimus dose at 16 hours after the once daily cyclosporine dose.

SIROLIMUS PHARMACOKINETIC PARAMETERS (MEAN ± SD) IN PEDIATRIC RENAL TRANSPLANT PATIENTS (MULTIPLE DOSE CONCENTRATION CONTROL)a,b
Age
(y)
n Body
weight
(kg)
Cmax,ss
(ng/mL)
tmax,ss
(h)
Cmin,ss
(ng/mL)
AUCτ,ss
(ng•h/mL)
CL/Fc
(mL/h/kg)
CL/Fc
(L/h/m2)

a: Sirolimus co-administered with cyclosporine oral solution (MODIFIED) (e.g., Neoral Oral Solution) and/or cyclosporine capsules (MODIFIED) (e.g., Neoral Soft Gelatin Capsules).
b: As measured by Liquid Chromatographic/Tandem Mass Spectrometric Method (LC/MS/MS).
c: Oral-dose clearance adjusted by either body weight (kg) or body surface area (m2).

6-11 8 27 ± 10 22.1 ± 8.9 5.88 ± 4.05 10.6 ± 4.3 356 ± 127 214 ± 129 5.4 ± 2.8
12-18 14 52 ± 15 34.5 ± 12.2 2.7 ± 1.5 14.7 ± 8.6 466 ± 236 136 ± 57 4.7 ± 1.9

The table below summarizes pharmacokinetic data obtained in pediatric dialysis patients with chronically impaired renal function.

SIROLIMUS PHARMACOKINETIC PARAMETERS (MEAN ± SD) IN PEDIATRIC PATIENTS WITH STABLE CHRONIC RENAL FAILURE MAINTAINED ON HEMODIALYSIS OR PERITONEAL DIALYSIS (1, 3, 9, 15 MG/M2 SINGLE DOSE)*
Age Group (y) n tmax (h) t1/2 (h) CL/F (mL/h/kg)

* All subjects received sirolimus oral solution

5-11 9 1.1 ± 0.5 71 ± 40 580 ± 450
12-18 11 0.79 ± 0.17 55 ± 18 450 ± 232

Geriatric: Clinical studies of Rapamune did not include a sufficient number of patients >65 years of age to determine whether they will respond differently than younger patients. After the administration of Rapamune Oral Solution, sirolimus trough concentration data in 35 renal transplant patients >65 years of age were similar to those in the adult population (n = 822) 18 to 65 years of age. Similar results were obtained after the administration of Rapamune Tablets to 12 renal transplant patients >65 years of age compared with adults (n = 167) 18 to 65 years of age.

Gender: After the administration of Rapamune Oral Solution, sirolimus oral dose clearance in males was 12% lower than that in females; male subjects had a significantly longer t1/2 than did female subjects (72.3 hours versus 61.3 hours). A similar trend in the effect of gender on sirolimus oral dose clearance and t1/2 was observed after the administration of Rapamune Tablets. Dose adjustments based on gender are not recommended.

Race: In large phase 3 trials (Studies 1 and 2) using Rapamune Oral Solution and cyclosporine oral solution (MODIFIED) (e.g., Neoral® Oral Solution) and/or cyclosporine capsules (MODIFIED) (e.g., Neoral® Soft Gelatin Capsules), there were no significant differences in mean trough sirolimus concentrations over time between black (n = 139) and non-black (n = 724) patients during the first 6 months after transplantation at sirolimus doses of 2 mg/day and 5 mg/day. Similarly, after administration of Rapamune Tablets (2 mg/day) in a phase III trial, mean sirolimus trough concentrations over 6 months were not significantly different among black (n = 51) and non-black (n = 128) patients.

Clinical Studies

Rapamune® Oral Solution: The safety and efficacy of Rapamune® Oral Solution for the prevention of organ rejection following renal transplantation were assessed in two randomized, double-blind, multicenter, controlled trials. These studies compared two dose levels of Rapamune Oral Solution (2 mg and 5 mg, once daily) with azathioprine (Study 1) or placebo (Study 2) when administered in combination with cyclosporine and corticosteroids. Study 1 was conducted in the United States at 38 sites. Seven hundred nineteen (719) patients were enrolled in this trial and randomized following transplantation; 284 were randomized to receive Rapamune Oral Solution 2 mg/day, 274 were randomized to receive Rapamune Oral Solution 5 mg/day, and 161 to receive azathioprine 2-3 mg/kg/day. Study 2 was conducted in Australia, Canada, Europe, and the United States, at a total of 34 sites. Five hundred seventy-six (576) patients were enrolled in this trial and randomized before transplantation; 227 were randomized to receive Rapamune Oral Solution 2 mg/day, 219 were randomized to receive Rapamune Oral Solution 5 mg/day, and 130 to receive placebo. In both studies, the use of antilymphocyte antibody induction therapy was prohibited. In both studies, the primary efficacy endpoint was the rate of efficacy failure in the first 6 months after transplantation. Efficacy failure was defined as the first occurrence of an acute rejection episode (confirmed by biopsy), graft loss, or death.

The tables below summarize the results of the primary efficacy analyses from these trials. Rapamune Oral Solution, at doses of 2 mg/day and 5 mg/day, significantly reduced the incidence of efficacy failure (statistically significant at the<0.025 level; nominal significance level adjusted for multiple [2] dose comparisons) at 6 months following transplantation compared with both azathioprine and placebo.

INCIDENCE (%) OF EFFICACY FAILURE AT 6 AND 24 MONTHS FOR STUDY 1a,b
Parameter Rapamune®
Oral Solution
2 mg/day
(n = 284)
Rapamune®
Oral Solution
5 mg/day
(n = 274)
Azathioprine
2-3 mg/kg/day
(n = 161)

a: Patients received cyclosporine and corticosteroids.
b: Includes patients who prematurely discontinued treatment.
c: Primary endpoint.

Efficacy failure at 6 monthsc 18.7 16.8 32.3
Components of efficacy failure
   Biopsy-proven acute rejection 16.5 11.3 29.2
   Graft loss 1.1 2.9 2.5
   Death 0.7 1.8 0
   Lost to follow-up 0.4 0.7 0.6
Efficacy failure at 24 months 32.8 25.9 36.0
Components of efficacy failure
   Biopsy-proven acute rejection 23.6 17.5 32.3
   Graft loss 3.9 4.7 3.1
   Death 4.2 3.3 0
   Lost to follow-up 1.1 0.4 0.6
INCIDENCE (%) OF EFFICACY FAILURE AT 6 AND 36 MONTHS FOR STUDY 2a,b
Parameter Rapamune®
Oral Solution
2 mg/day
(n = 227)
Rapamune®
Oral Solution
5 mg/day
(n = 219)
Placebo
(n = 130)

a: Patients received cyclosporine and corticosteroids.
b: Includes patients who prematurely discontinued treatment.
c: Primary endpoint.

Efficacy failure at 6 monthsc 30.0 25.6 47.7
Components of efficacy failure
   Biopsy-proven acute rejection 24.7 19.2 41.5
   Graft loss 3.1 3.7 3.9
   Death 2.2 2.7 2.3
   Lost to follow-up 0 0 0
Efficacy failure at 36 months 44.1 41.6 54.6
Components of efficacy failure
   Biopsy-proven acute rejection 32.2 27.4 43.9
   Graft loss 6.2 7.3 4.6
   Death 5.7 5.9 5.4
   Lost to follow-up 0 0.9 0.8

Patient and graft survival at 1 year were co-primary endpoints. The table below shows graft and patient survival at 1 and 2 years in Study 1 and 1 and 3 years in Study 2. The graft and patient survival rates were similar in patients treated with Rapamune and comparator-treated patients.

GRAFT AND PATIENT SURVIVAL (%) FOR STUDY 1 (12 AND 24 MONTHS) AND STUDY 2 (12 AND 36 MONTHS)a,b
Parameter Rapamune®
Oral Solution
2 mg/day
Rapamune®
Oral Solution
5 mg/day
Azathioprine
2-3 mg/kg/day
Placebo

a: Patients received cyclosporine and corticosteroids.
b: Includes patients who prematurely discontinued treatment.

Study 1 (n = 284) (n = 274) (n = 161)
   Graft survival
      Month 12 94.7 92.7 93.8
      Month 24 85.2 89.1 90.1
   Patient survival
      Month 12 97.2 96.0 98.1
      Month 24 92.6 94.9 96.3
Study 2 (n = 227) (n = 219) (n = 130)
   Graft survival
      Month 12 89.9 90.9 87.7
      Month 36 81.1 79.9 80.8
   Patient survival
      Month 12 96.5 95.0 94.6
      Month 36 90.3 89.5 90.8

The reduction in the incidence of first biopsy-confirmed acute rejection episodes in patients treated with Rapamune compared with the control groups included a reduction in all grades of rejection.

In Study 1, which was prospectively stratified by race within center, efficacy failure was similar for Rapamune Oral Solution 2 mg/day and lower for Rapamune Oral Solution 5 mg/day compared with azathioprine in black patients. In Study 2, which was not prospectively stratified by race, efficacy failure was similar for both Rapamune Oral Solution doses compared with placebo in black patients. The decision to use the higher dose of Rapamune Oral Solution in black patients must be weighed against the increased risk of dose-dependent adverse events that were observed with the Rapamune Oral Solution 5-mg dose (see ADVERSE REACTIONS).

PERCENTAGE OF EFFICACY FAILURE BY RACE AT 6 MONTHSa,b
Parameter Rapamune®
Oral Solution
2 mg/day
Rapamune®
Oral Solution
5 mg/day
Azathioprine
2-3 mg/kg/day
Placebo

a: Patients received cyclosporine and corticosteroids.
b: Includes patients who prematurely discontinued treatment.

Study 1
   Black (n = 166) 34.9 (n = 63) 18.0 (n = 61) 33.3 (n = 42)
   Non-black (n = 553) 14.0 (n = 221) 16.4 (n = 213) 31.9 (n = 119)
Study 2
   Black (n = 66) 30.8 (n = 26) 33.7 (n = 27) 38.5 (n = 13)
   Non-black (n = 510) 29.9 (n = 201) 24.5 (n = 192) 48.7 (n = 117)

Mean glomerular filtration rates (GFR) post transplant were calculated by using the Nankivell equation at 12 and 24 months for Study 1, and 12 and 36 months for Study 2. Mean GFR was lower in patients treated with cyclosporine and Rapamune Oral Solution compared with those treated with cyclosporine and the respective azathioprine or placebo control.

OVERALL CALCULATED GLOMERULAR FILTRATION RATES (Mean ± SEM, cc/min) BY NANKIVELL EQUATION POST TRANSPLANTa,b
Parameter Rapamune®
Oral Solution
2 mg/day
Rapamune®
Oral Solution
5 mg/day
Azathioprine
2-3 mg/kg/day
Placebo

a: Includes patients who prematurely discontinued treatment.
b: Patients who had a graft loss were included in the analysis with GFR set to 0.0.

Study 1
   Month 12 57.4 ± 1.3
(n = 269)
54.6 ± 1.3
(n = 248)
64.1 ± 1.6)
(n = 149)
   Month 24 58.4 ± 1.5
(n = 221)
52.6 ± 1.5
(n = 222)
62.4 ± 1.9
(n = 132)
Study 2
   Month 12 52.4 ± 1.5
(n = 211)
51.5 ± 1.5
(n = 199)
58.0 ± 2.1
(n = 117)
   Month 36 48.1 ± 1.8
(n = 183)
46.1 ± 2.0
(n = 177)
53.4 ± 2.7
(n = 102)

Within each treatment group in Studies 1 and 2, mean GFR at one year post transplant was lower in patients who experienced at least 1 episode of biopsy-proven acute rejection, compared with those who did not.

Renal function should be monitored and appropriate adjustment of the immunosuppression regimen should be considered in patients with elevated or increasing serum creatinine levels (see PRECAUTIONS).

Rapamune® Tablets: The safety and efficacy of Rapamune Oral Solution and Rapamune Tablets for the prevention of organ rejection following renal transplantation were compared in a randomized multicenter controlled trial (Study 3). This study compared a single dose level (2 mg, once daily) of Rapamune Oral Solution and Rapamune Tablets when administered in combination with cyclosporine and corticosteroids. The study was conducted at 30 centers in Australia, Canada, and the United States. Four hundred seventy-seven (477) patients were enrolled in this study and randomized before transplantation; 238 patients were randomized to receive Rapamune Oral Solution 2 mg/day and 239 patients were randomized to receive Rapamune Tablets 2 mg/day. In this study, the use of antilymphocyte antibody induction therapy was prohibited. The primary efficacy endpoint was the rate of efficacy failure in the first 3 months after transplantation. Efficacy failure was defined as the first occurrence of an acute rejection episode (confirmed by biopsy), graft loss, or death.

The table below summarizes the result of the efficacy failure analysis at 3 and 6 months from this trial. The overall rate of efficacy failure at 3 months, the primary endpoint, in the tablet treatment group was equivalent to the rate in the oral solution treatment group.

INCIDENCE (%) OF EFFICACY FAILURE AT 3 AND 6 MONTHS: STUDY 3a,b
Rapamune®
Oral Solution
(n = 238)
Rapamune®
Tablets
(n = 239)

a: Patients received cyclosporine and corticosteroids.
b: Includes patients who prematurely discontinued treatment.
c: Efficacy failure at 3 months was the primary endpoint.

Efficacy Failure at 3 monthsc 23.5 24.7
Components of efficacy failure
   Biopsy-proven acute rejection 18.9 17.6
   Graft loss 3.4 6.3
   Death 1.3 0.8
Efficacy Failure at 6 months 26.1 27.2
Components of efficacy failure
   Biopsy-proven acute rejection 21.0 19.2
   Graft loss 3.4 6.3
   Death 1.7 1.7

Graft and patient survival at 12 months were co-primary endpoints. There was no significant difference between the oral solution and tablet formulations for both graft and patient survival. Graft survival was 92.0% and 88.7% for the oral solution and tablet treatment groups, respectively. The patient survival rates in the oral solution and tablet treatment groups were 95.8% and 96.2%, respectively.

The mean GFR at 12 months, calculated by the Nankivell equation, were not significantly different for the oral solution group and for the tablet group.

The table below summarizes the mean GFR at one-year post-transplantation for all patients in Study 3 who had serum creatinine measured at 12 months.

OVERALL CALCULATED GLOMERULAR FILTRATION RATES (CC/MIN) BY NANKIVELL EQUATION AT 12 MONTHS POST TRANSPLANT: STUDY 3a,b
Rapamune®
Oral Solution
Rapamune®
Tablets

a: Includes patients who prematurely discontinued treatment.
b: Patients who had a graft loss were included in the analysis with GFR set to 0.0.

Mean ± SEM 53.1 ± 1.7
(n = 229)
51.7 ± 1.7
(n = 225)

In Study 4 (cyclosporine withdrawal study), the safety and efficacy of Rapamune as a maintenance regimen were assessed following cyclosporine withdrawal at 3 to 4 months post renal transplantation. Study 4 was a randomized, multicenter, controlled trial conducted at 57 centers in Australia, Canada, and Europe. Five hundred twenty-five (525) patients were enrolled. All patients in this study received the tablet formulation. This study compared patients who were administered Rapamune, cyclosporine, and corticosteroids continuously with patients who received the same standardized therapy for the first 3 months after transplantation (prerandomization period) followed by the withdrawal of cyclosporine. During cyclosporine withdrawal the Rapamune dosages were adjusted to achieve targeted sirolimus whole blood trough concentration ranges (16 to 24 ng/mL until month 12, then 12 to 20 ng/mL thereafter, expressed as chromatographic assay values; see DOSAGE AND ADMINISTRATION). At 3 months, 430 patients were equally randomized to either Rapamune with cyclosporine therapy or Rapamune as a maintenance regimen following cyclosporine withdrawal.

Eligibility for randomization included no Banff Grade 3 acute rejection episode or vascular rejection in the 4 weeks before random assignment; serum creatinine ≤ 4.5 mg/dL; and adequate renal function to support cyclosporine withdrawal (in the opinion of the investigator). The primary efficacy endpoint was graft survival at 12 months after transplantation. Secondary efficacy endpoints were the rate of biopsy-confirmed acute rejection, patient survival, incidence of efficacy failure (defined as the first occurrence of either biopsy-proven acute rejection, graft loss, or death), and treatment failure (defined as the first occurrence of either discontinuation, acute rejection, graft loss, or death).

The safety and efficacy of cyclosporine withdrawal in high-risk patients have not been adequately studied and it is therefore not recommended. This includes patients with Banff grade III acute rejection or vascular rejection prior to cyclosporine withdrawal, those who are dialysis-dependent, serum creatinine > 4.5 mg/dL, black patients, re-transplants, multi-organ transplants, or patients with high panel of reactive antibodies (See INDICATIONS AND USAGE).

The following table summarizes the resulting graft and patient survival at 12, 24, and 36 months for this trial. At 12, 24, and 36 months, graft and patient survival were similar for both groups.

GRAFT AND PATIENT SURVIVAL (%): STUDY 4 (CYCLOSPORINE WITHDRAWAL STUDY)a
Parameter Rapamune with
Cyclosporine Therapy
(n = 215)
Rapamune Following Cyclosporine
Withdrawal
(n = 215)

a: Includes patients who prematurely discontinued treatment.
b: Primary efficacy endpoint.
c. Survival including loss to follow-up as an event.
d. Initial planned duration of the study.

Graft Survival
   Month 12b 95.3c 97.2
   Month 24 91.6 94.0
   Month 36d 87.0 91.6
Patient Survival
   Month 12 97.2 98.1
   Month 24 94.4 95.8
   Month 36d 91.6 94.0

The following table summarizes the results of first biopsy-proven acute rejection at 12 and 36 months. There was a significant difference in first biopsy-proven rejection between the two groups during post-randomization through 12 months. Most of the post-randomization acute rejections occurred in the first 3 months following randomization.

INCIDENCE OF FIRST BIOPSY-PROVEN ACUTE REJECTION (%) BY TREATMENT GROUP AT 36 MONTHS: STUDY 4 (CYCLOSPORINE WITHDRAWAL STUDY)a,b
Period Rapamune with Cyclosporine Therapy
(n = 215)
Rapamune Following Cyclosporine Withdrawal
(n = 215)

a: Includes patients who prematurely discontinued treatment.
b: All patients received corticosteroids.
c: Randomization occurred at 3 months ± 2 weeks.




1

eapamune oral solution,tablets, dapamune oral solution,tablets, fapamune oral solution,tablets, tapamune oral solution,tablets, 5apamune oral solution,tablets, 4apamune oral solution,tablets, rzpamune oral solution,tablets, rspamune oral solution,tablets, rwpamune oral solution,tablets, rqpamune oral solution,tablets, raoamune oral solution,tablets, ralamune oral solution,tablets, ra-amune oral solution,tablets, ra0amune oral solution,tablets, rapzmune oral solution,tablets, rapsmune oral solution,tablets, rapwmune oral solution,tablets, rapqmune oral solution,tablets, rapanune oral solution,tablets, rapakune oral solution,tablets, rapajune oral solution,tablets, rapamyne oral solution,tablets, rapamhne oral solution,tablets, rapamjne oral solution,tablets, rapamine oral solution,tablets, rapam8ne oral solution,tablets, rapam7ne oral solution,tablets, rapamube oral solution,tablets, rapamume oral solution,tablets, rapamuje oral solution,tablets, rapamuhe oral solution,tablets, rapamunw oral solution,tablets, rapamuns oral solution,tablets, rapamund oral solution,tablets, rapamunr oral solution,tablets, rapamun4 oral solution,tablets, rapamun3 oral solution,tablets, rapamune iral solution,tablets, rapamune kral solution,tablets, rapamune lral solution,tablets, rapamune pral solution,tablets, rapamune 0ral solution,tablets, rapamune 9ral solution,tablets, rapamune oeal solution,tablets, rapamune odal solution,tablets, rapamune ofal solution,tablets, rapamune otal solution,tablets, rapamune o5al solution,tablets, rapamune o4al solution,tablets, rapamune orzl solution,tablets, rapamune orsl solution,tablets, rapamune orwl solution,tablets, rapamune orql solution,tablets, rapamune orak solution,tablets, rapamune orap solution,tablets, rapamune orao solution,tablets, rapamune oral aolution,tablets, rapamune oral zolution,tablets, rapamune oral xolution,tablets, rapamune oral dolution,tablets, rapamune oral eolution,tablets, rapamune oral wolution,tablets, rapamune oral silution,tablets, rapamune oral sklution,tablets, rapamune oral sllution,tablets, rapamune oral splution,tablets, rapamune oral s0lution,tablets, rapamune oral s9lution,tablets, rapamune oral sokution,tablets, rapamune oral sopution,tablets, rapamune oral sooution,tablets, rapamune oral solytion,tablets, rapamune oral solhtion,tablets, rapamune oral soljtion,tablets, rapamune oral solition,tablets, rapamune oral sol8tion,tablets, rapamune oral sol7tion,tablets, rapamune oral solurion,tablets, rapamune oral solufion,tablets, rapamune oral solugion,tablets, rapamune oral soluyion,tablets, rapamune oral solu6ion,tablets, rapamune oral solu5ion,tablets, rapamune oral solutuon,tablets, rapamune oral solutjon,tablets, rapamune oral solutkon,tablets, rapamune oral solutoon,tablets, rapamune oral solut9on,tablets, rapamune oral solut8on,tablets, rapamune oral solutiin,tablets, rapamune oral solutikn,tablets, rapamune oral solutiln,tablets, rapamune oral solutipn,tablets, rapamune oral soluti0n,tablets, rapamune oral soluti9n,tablets, rapamune oral solutiob,tablets, rapamune oral solutiom,tablets, rapamune oral solutioj,tablets, rapamune oral solutioh,tablets, rapamune oral solution,rablets, rapamune oral solution,fablets, rapamune oral solution,gablets, rapamune oral solution,yablets, rapamune oral solution,6ablets, rapamune oral solution,5ablets, rapamune oral solution,tzblets, rapamune oral solution,tsblets, rapamune oral solution,twblets, rapamune oral solution,tqblets, rapamune oral solution,tavlets, rapamune oral solution,tanlets, rapamune oral solution,tahlets, rapamune oral solution,taglets, rapamune oral solution,tabkets, rapamune oral solution,tabpets, rapamune oral solution,taboets, rapamune oral solution,tablwts, rapamune oral solution,tablsts, rapamune oral solution,tabldts, rapamune oral solution,tablrts, rapamune oral solution,tabl4ts, rapamune oral solution,tabl3ts, rapamune oral solution,tablers, rapamune oral solution,tablefs, rapamune oral solution,tablegs, rapamune oral solution,tableys, rapamune oral solution,table6s, rapamune oral solution,table5s, rapamune oral solution,tableta, rapamune oral solution,tabletz, rapamune oral solution,tabletx, rapamune oral solution,tabletd, rapamune oral solution,tablete, rapamune oral solution,tabletw, apamune oral solution,tablets, rpamune oral solution,tablets, raamune oral solution,tablets, rapmune oral solution,tablets, rapaune oral solution,tablets, rapamne oral solution,tablets, rapamue oral solution,tablets, rapamun oral solution,tablets, rapamuneoral solution,tablets, rapamune ral solution,tablets, rapamune oal solution,tablets, rapamune orl solution,tablets, rapamune ora solution,tablets, rapamune oralsolution,tablets, rapamune oral olution,tablets, rapamune oral slution,tablets, rapamune oral soution,tablets, rapamune oral soltion,tablets, rapamune oral soluion,tablets, rapamune oral soluton,tablets, rapamune oral solutin,tablets, rapamune oral solutio,tablets, rapamune oral solutiontablets, rapamune oral solution,ablets, rapamune oral solution,tblets, rapamune oral solution,talets, rapamune oral solution,tabets, rapamune oral solution,tablts, rapamune oral solution,tables, rapamune oral solution,tablet, arpamune oral solution,tablets, rpaamune oral solution,tablets, raapmune oral solution,tablets, rapmaune oral solution,tablets, rapaumne oral solution,tablets, rapamnue oral solution,tablets, rapamuen oral solution,tablets, rapamun eoral solution,tablets, rapamuneo ral solution,tablets, rapamune roal solution,tablets, rapamune oarl solution,tablets, rapamune orla solution,tablets, rapamune ora lsolution,tablets, rapamune orals olution,tablets, rapamune oral oslution,tablets, rapamune oral sloution,tablets, rapamune oral soultion,tablets, rapamune oral soltuion,tablets, rapamune oral soluiton,tablets, rapamune oral solutoin,tablets, rapamune oral solutino,tablets, rapamune oral solutio,ntablets, rapamune oral solutiont,ablets, rapamune oral solution,atblets, rapamune oral solution,tbalets, rapamune oral solution,talbets, rapamune oral solution,tabelts, rapamune oral solution,tabltes, rapamune oral solution,tablest, rrapamune oral solution,tablets, raapamune oral solution,tablets, rappamune oral solution,tablets, rapaamune oral solution,tablets, rapammune oral solution,tablets, rapamuune oral solution,tablets, rapamunne oral solution,tablets, rapamunee oral solution,tablets, rapamune oral solution,tablets, rapamune ooral solution,tablets, rapamune orral solution,tablets, rapamune oraal solution,tablets, rapamune orall solution,tablets, rapamune oral solution,tablets, rapamune oral ssolution,tablets, rapamune oral soolution,tablets, rapamune oral sollution,tablets, rapamune oral soluution,tablets, rapamune oral soluttion,tablets, rapamune oral solutiion,tablets, rapamune oral solutioon,tablets, rapamune oral solutionn,tablets, rapamune oral solution,,tablets, rapamune oral solution,ttablets, rapamune oral solution,taablets, rapamune oral solution,tabblets, rapamune oral solution,tabllets, rapamune oral solution,tableets, rapamune oral solution,tabletts, rapamune oral solution,tabletss, etc.

USA hospitals | Natural mosquito repellent | New 401k contribution limits | PMS | Blue waffles disease | Keratosis pilaris on face tretment


© Copyright by Drugspedia.net 2006-2007. All rights reserved